Medigen Vaccine Biologics Corp.
Quick facts
| Founded | 2012 |
|---|
Phase 3 pipeline
- Envacgen® · Immunology / Infectious Disease
Envacgen is a recombinant protein subunit vaccine designed to stimulate immune responses against specific disease targets through antigen presentation. - EV71vac · Immunology / Infectious Disease
EV71vac is an inactivated vaccine that stimulates the immune system to produce antibodies and cellular immunity against Enterovirus 71 (EV71). - GC FLU Quadrivalent · Immunology / Infectious Disease
GC FLU Quadrivalent is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus. - MVC-COV1901 · Immunology / Infectious Disease
MVC-COV1901 is a protein subunit vaccine that stimulates immune responses against SARS-CoV-2 by presenting viral spike protein antigens to the immune system.
Phase 2 pipeline
- EV71 with adjuvant aluminium phosphate
- Full dose of MVC-COV1901
- Half dose of mRNA-1273
- Half dose of MVC-COV1901
Phase 1 pipeline
- AT-501 High Dose vaccine
- AT-501 High Dose vaccine with Adjuvant
- AT-501 Low Dose vaccine
- AT-501 Low Dose vaccine with Adjuvant
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Medigen Vaccine Biologics Corp. portfolio CI brief
- Medigen Vaccine Biologics Corp. pipeline updates RSS
Frequently asked questions about Medigen Vaccine Biologics Corp.
What is Medigen Vaccine Biologics Corp.'s pipeline?
Medigen Vaccine Biologics Corp. has 4 drugs in Phase 3, 4 in Phase 2, 4 in Phase 1. Late-stage candidates include Envacgen®, EV71vac, GC FLU Quadrivalent, MVC-COV1901.
When was Medigen Vaccine Biologics Corp. founded?
Medigen Vaccine Biologics Corp. was founded in 2012.
Related
- Sector hub: All tracked pharma companies